Search - tctmd.com

Displaying 481 - 500 of 2446

Sort: Relevancy | Date

News Conference News AHA 2023

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Michael O'Riordan

November 12, 2023

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

Todd Neale

November 11, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News AHA 2023

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

L.A. McKeown

November 11, 2023

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2023

Shelley Wood

November 01, 2023

News Conference News TCT 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

Todd Neale

October 31, 2023

Presentation TCT 2023

TCT 340: Sex Differences in Patients with Three-vessel Coronary Artery Disease Undergoing FFR-guided PCI or CABG: A Pre-specified Analysis of the FAME 3 Trial

Presenter: Kuniaki Takahashi

October 26, 2023

Presentation TCT 2023

TCT 158: The Impact of Sex And Age On Long-term Outcome After Percutaneous Coronary Interventions – A Pooled Analysis Of The Randomized Controlled SORT OUT Trials

Presenter: Emil Holck

October 26, 2023

Presentation TCT 2023

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

Presenter: Michael Bloch

October 25, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

Presentation TCT 2023

Hypertension Care Pathway with uRDN: Experiences from Clinical Trials

Presenter: NULL

October 25, 2023

Presentation TCT 2023

TCT 140: Combined Coexistence of Multiple Vulnerable Plaque Features is Associated with Incremental Rates of Adverse Events in Patients with Diabetes Mellitus. New Insights From the COMBINE OCT-FFR trial

Presenter: David del Val

October 25, 2023

Presentation TCT 2023

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Presenter: Michel Azizi

October 25, 2023

News Conference News TCT 2023

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

L.A. McKeown

October 24, 2023

Presentation TCT 2023

Trialist Perspectives

Presenter: Felix Mahfoud

October 24, 2023

Advertisement

Slash Dietary Sodium, Slash Blood Pressure: CARDIA-SSBP

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

MINT Hints at Benefits of Liberal Transfusions in Acute MI With Anemia

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Approves Paradise Renal Denervation System: What Comes Next?

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

What’s Going to Be Hot at AHA 2023

TCTMD’s Top 10 Most Popular Stories for October 2023

RADIANCE: 'Modest' Renal Denervation Effect Remains at 6 Months

TCT 340: Sex Differences in Patients with Three-vessel Coronary Artery Disease Undergoing FFR-guided PCI or CABG: A Pre-specified Analysis of the FAME 3 Trial

TCT 158: The Impact of Sex And Age On Long-term Outcome After Percutaneous Coronary Interventions – A Pooled Analysis Of The Randomized Controlled SORT OUT Trials

TCT 325: Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation: Patient-Level Pooled Analysis of the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO and RADIANCE-HTN TRIO Trials

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Hypertension Care Pathway with uRDN: Experiences from Clinical Trials

TCT 140: Combined Coexistence of Multiple Vulnerable Plaque Features is Associated with Incremental Rates of Adverse Events in Patients with Diabetes Mellitus. New Insights From the COMBINE OCT-FFR trial

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door?

Trialist Perspectives

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content